DOP2012000224A - Compuesto heterociclico - Google Patents

Compuesto heterociclico

Info

Publication number
DOP2012000224A
DOP2012000224A DO2012000224A DO2012000224A DOP2012000224A DO P2012000224 A DOP2012000224 A DO P2012000224A DO 2012000224 A DO2012000224 A DO 2012000224A DO 2012000224 A DO2012000224 A DO 2012000224A DO P2012000224 A DOP2012000224 A DO P2012000224A
Authority
DO
Dominican Republic
Prior art keywords
heterociclical
compound
heterociclical compound
Prior art date
Application number
DO2012000224A
Other languages
English (en)
Inventor
Yuya Oguro
Misaki Homma
Toru Miyazaki
Osamu Kurasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000224(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2012000224A publication Critical patent/DOP2012000224A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DO2012000224A 2010-02-17 2012-08-15 Compuesto heterociclico DOP2012000224A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010031899 2010-02-17
JP2010131950 2010-06-09

Publications (1)

Publication Number Publication Date
DOP2012000224A true DOP2012000224A (es) 2013-01-31

Family

ID=44482985

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000224A DOP2012000224A (es) 2010-02-17 2012-08-15 Compuesto heterociclico

Country Status (37)

Country Link
US (6) US8722660B2 (es)
EP (2) EP3533797B1 (es)
JP (1) JP5689454B2 (es)
KR (1) KR101735868B1 (es)
CN (1) CN102844320B (es)
AU (1) AU2011216404B2 (es)
BR (1) BR112012020311B1 (es)
CA (1) CA2790284C (es)
CL (1) CL2012002250A1 (es)
CO (1) CO6592104A2 (es)
CR (1) CR20120448A (es)
CY (1) CY1121792T1 (es)
DK (1) DK2540728T3 (es)
DO (1) DOP2012000224A (es)
EA (1) EA020724B1 (es)
EC (1) ECSP12012160A (es)
ES (1) ES2733221T3 (es)
GE (1) GEP20146202B (es)
HR (1) HRP20190947T1 (es)
HU (1) HUE043514T2 (es)
IL (1) IL221442A0 (es)
LT (1) LT2540728T (es)
MA (1) MA34064B1 (es)
ME (1) ME03410B (es)
MX (1) MX353500B (es)
MY (1) MY164776A (es)
NZ (1) NZ602089A (es)
PE (1) PE20130184A1 (es)
PH (1) PH12012501650B1 (es)
PL (1) PL2540728T3 (es)
PT (1) PT2540728T (es)
RS (1) RS58796B1 (es)
SG (1) SG183304A1 (es)
SI (1) SI2540728T1 (es)
SM (1) SMT201900385T1 (es)
TN (1) TN2012000401A1 (es)
WO (1) WO2011102399A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2603214A4 (en) * 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
US9974795B2 (en) 2014-01-31 2018-05-22 Carna Biosciences, Inc. Anticancer agent composition
TW201620879A (zh) 2014-04-28 2016-06-16 杜邦股份有限公司 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
CA3007840C (en) 2015-12-07 2020-09-15 Zymergen Inc. Microbial strain improvement by a htp genomic engineering platform
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
TWI738748B (zh) * 2016-03-28 2021-09-11 日商武田藥品工業有限公司 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形
EA035560B1 (ru) * 2016-07-28 2020-07-07 Такеда Фармасьютикал Компани Лимитед Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
JP7071383B2 (ja) 2016-11-08 2022-05-18 キャンサー・リサーチ・テクノロジー・リミテッド ｃｄｃ７阻害剤としてのピリミジノン誘導体
US11155879B2 (en) * 2017-03-01 2021-10-26 Takeda Pharmaceutical Company Limited Method of predicting effects of CDC7 inhibitor
CN110381950B (zh) * 2017-05-21 2020-09-04 南京正济医药研究有限公司 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
WO2019194319A1 (en) * 2018-04-02 2019-10-10 Takeda Pharmaceutical Company Limited Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
TWI846703B (zh) 2018-06-19 2024-07-01 日商武田藥品工業股份有限公司 癌症治療方法
CA3106557A1 (en) * 2018-07-19 2020-01-23 Takeda Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
CA3113621A1 (en) 2018-09-24 2020-04-02 Sierra Oncology, Inc. Methods of treatment of cancer comprising cdc7 inhibitors
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
US20220235068A1 (en) * 2019-05-30 2022-07-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compounds as cdc7 inhibitors
KR20220035379A (ko) * 2019-07-19 2022-03-22 다케다 야쿠힌 고교 가부시키가이샤 암 치료를 위한 조합 요법
US20220389026A1 (en) * 2019-08-20 2022-12-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compound used as cdc7 inhibitor
US20230101747A1 (en) * 2019-12-06 2023-03-30 Schrödinger, Inc. Cyclic compounds and methods of using same
CN116490507A (zh) * 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
CN116472046B (zh) * 2020-11-30 2025-03-28 正大天晴药业集团股份有限公司 作为Cdc7抑制剂的盐型及其晶型
CN112661770B (zh) * 2020-12-24 2022-11-08 南京正济医药研究有限公司 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
EP4288050A1 (en) 2021-02-08 2023-12-13 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
WO2025160538A1 (en) * 2024-01-26 2025-07-31 The Board Of Regents Of The University Of Texas System Compositions and methods for treating hair graying and loss associated with aging
WO2025168620A1 (en) 2024-02-07 2025-08-14 Bayer Aktiengesellschaft Heteroaryl-substituted 4,5-dihydro-1h-2,4,5-oxadiazines as novel fungicides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
CA2423981A1 (en) 2000-09-29 2003-03-28 Kimiko Ichikawa Thienopyrimidine compounds and salts thereof and process for the preparation of the same
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
EP1383771A1 (en) 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
CN1823071B (zh) * 2003-06-11 2012-12-19 润生有限公司 用作钾通道抑制剂的噻吩并嘧啶衍生物
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2005014572A1 (en) 2003-08-08 2005-02-17 Pharmacia Italia S.P.A. Pyrimidylpyrrole derivatives active as kinase inhibitors
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2005095386A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP2495324B1 (en) 2004-04-09 2015-03-04 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
JP4545196B2 (ja) 2005-01-19 2010-09-15 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
US20080221107A1 (en) 2005-07-15 2008-09-11 Astrazeneca Ab Therapeutic Agents
AU2006285915B2 (en) 2005-08-30 2011-02-24 Asahi Kasei Pharma Corporation Sulfonamide compound
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070142414A1 (en) * 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
US20090030196A1 (en) 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008094909A2 (en) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
CA2728674A1 (en) 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis methods of use thereof
WO2010101302A1 (en) 2009-03-05 2010-09-10 Takeda Pharmaceutical Company Limited Thienopyrimidine as cdc7 kinase inhibitors
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
WO2011029782A1 (en) 2009-09-11 2011-03-17 Bayer Schering Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids

Also Published As

Publication number Publication date
US20130029969A1 (en) 2013-01-31
US8722660B2 (en) 2014-05-13
US9388195B2 (en) 2016-07-12
CN102844320A (zh) 2012-12-26
IL221442A0 (en) 2012-10-31
PL2540728T3 (pl) 2019-09-30
KR20130001246A (ko) 2013-01-03
CN102844320B (zh) 2016-03-23
HRP20190947T1 (hr) 2019-07-26
EA020724B1 (ru) 2015-01-30
DK2540728T3 (da) 2019-05-13
EP3533797B1 (en) 2023-12-20
MX353500B (es) 2018-01-16
AU2011216404B2 (en) 2016-04-07
EP2540728A4 (en) 2013-11-06
PT2540728T (pt) 2019-07-11
TN2012000401A1 (en) 2014-01-30
SI2540728T1 (sl) 2019-06-28
LT2540728T (lt) 2019-06-25
JPWO2011102399A1 (ja) 2013-06-17
RS58796B1 (sr) 2019-07-31
US9655900B2 (en) 2017-05-23
EP2540728B1 (en) 2019-04-10
PE20130184A1 (es) 2013-03-09
HUE043514T2 (hu) 2019-08-28
JP5689454B2 (ja) 2015-03-25
MY164776A (en) 2018-01-30
ECSP12012160A (es) 2013-03-28
US8921354B2 (en) 2014-12-30
US20140228352A1 (en) 2014-08-14
KR101735868B1 (ko) 2017-05-15
US8933069B2 (en) 2015-01-13
SG183304A1 (en) 2012-09-27
CO6592104A2 (es) 2013-01-02
CA2790284A1 (en) 2011-08-25
CL2012002250A1 (es) 2013-02-08
ME03410B (me) 2020-01-20
US20170209452A1 (en) 2017-07-27
SMT201900385T1 (it) 2019-09-09
PH12012501650B1 (en) 2018-11-07
WO2011102399A1 (ja) 2011-08-25
US20160310494A1 (en) 2016-10-27
CR20120448A (es) 2012-11-13
AU2011216404A1 (en) 2012-09-20
MA34064B1 (fr) 2013-03-05
BR112012020311A2 (pt) 2017-03-01
CA2790284C (en) 2019-01-08
PH12012501650A1 (en) 2012-10-22
EA201290800A1 (ru) 2013-03-29
EP3533797A1 (en) 2019-09-04
ES2733221T3 (es) 2019-11-28
US20150158882A1 (en) 2015-06-11
NZ602089A (en) 2014-05-30
US20140235615A1 (en) 2014-08-21
EP2540728A1 (en) 2013-01-02
GEP20146202B (en) 2014-11-25
MX2012009602A (es) 2012-12-17
BR112012020311B1 (pt) 2019-01-29
CY1121792T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
BR112013009935C8 (pt) compostos
PL2614063T3 (pl) Podstawione imidazopirydazyny
DK3225404T3 (da) Fluidpatron
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
EP2568873A4 (en) SAUGEINZUG
EP2529782A4 (en) INTRODUCER SLEEVE ASSEMBLY
DK2648516T3 (da) Substituerede pyridinon-pyridinylforbindelser
CO6801726A2 (es) Compuestos
PT2626350E (pt) Composto de ciclopropano
DE112011104226A5 (de) Käfigmutter
DK2649070T3 (da) Triazolpyridinforbindelser
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011101226A5 (de) Linearwegmesssystem
DE112011102080A5 (de) Kupplungszentralausrücker
BR112012026803A2 (pt) composto
DK2442899T3 (da) Rotorskive
DK2539163T3 (da) Dækventil
DE102010038420A8 (de) Reinigungungsvorrichtung
DK2448659T3 (da) Rotorskive
DE102011002623A8 (de) Ventilsteuerzeitversteller
EP2441726A4 (en) LIFT
EP2571003A4 (en) RISK CALCULATION APPARATUS